<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4180179</article-id><article-id pub-id-type="publisher-id">1129-2377-15-S1-C9</article-id><article-id pub-id-type="doi">10.1186/1129-2377-15-S1-C9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>EHMTI-0202. Study protocol of BoTN: a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of botulinum toxin injections in the treatment of trigeminal neuralgia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Burmeister</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Holle</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Bock</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Ose</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Diener</surname><given-names>HC</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Obermann</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Neurology, University Hospital Essen, Essen, Germany</aff><aff id="I2"><label>2</label>Institute for Medical Informatics and Epidemiology, University Hospital Essen, Essen, Germany</aff><aff id="I3"><label>3</label>Center for Clinical Trials, University Hospital Essen, Essen, Germany</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2014</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014</named-content><named-content content-type="supplement-sponsor">Publication costs for this supplement were funded by the conference.</named-content></supplement><fpage>C9</fpage><lpage>C9</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Burmeister et al; licensee Springer.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Burmeister et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/15/S1/C9"/><conference><conf-date>18-21 September 2014</conf-date><conf-name>4th European Headache and Migraine Trust International Congress: EHMTIC 2014</conf-name><conf-loc>Copenhagen, Denmark</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Trigeminal neuralgia (TN) is a chronic disorder characterized by paroxysmal facial pain. Adequate prophylactic drug therapy is often limited by the lack of efficacy and intolerance due to central nervous system side effects.</p><p>Subcutaneous injections of botuinum toxin type A (BT-A) are a promising treatment option for patients with insatisfactory response to drug therapy or neurosurgical intervention.</p><p>This is the study protocoll of a prospective, placebo-controlled, double blind clinical trial investigating the add-on therapy of subcutaneous of BT-A injections to standard treatment.</p></sec><sec><title>Methods and design</title><p>BoTN is a prospective, randomized, double-blind, placebo-controlled trial with a randomized withdrawal design. Eligible patients with classic TN who are otherwise refractory to medical and neurosurgical treatment will receive subcutaneous injections of BT-A into injection sites of the affected trigeminal branch.</p><p>In the first phase phase all patients will receive verum in a single blinded intervention and twelve weeks later therapy responders will be 1:1 allocated to the verum or placebo (saline) arm. This time the intervention is double blind and injections will be done at the same sites.</p><p>This trial will be conducted in a tertiary outpatient clinic specialized in the treatment of headache and facial pain.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>BoTN is designed to assess the efficacy and safety of local BT-A injections in additon to standard prophylactic treatment.</p><p>No conflict of interest.</p></sec></body></article>